Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 1
2019 2
2020 6
2021 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Gurwith M, Condit RC, Excler JL, Robertson JS, Kim D, Fast PE, Drew S, Wood D, Klug B, Whelan M, Mallett Moore T, Khuri-Bulos N, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. Gurwith M, et al. Vaccine. 2020 Nov 17;38(49):7702-7707. doi: 10.1016/j.vaccine.2020.09.042. Epub 2020 Oct 16. Vaccine. 2020. PMID: 33070999 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
Kochhar S, Kim D, Excler JL, Condit RC, Robertson JS, Drew S, Whelan M, Wood D, Fast PE, Gurwith M, Klug B, Khuri-Bulos N, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Vaccine. 2020 Jul 31;38(35):5734-5739. doi: 10.1016/j.vaccine.2020.06.044. Epub 2020 Jul 9. Vaccine. 2020. PMID: 32653276 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.
Kim D, Robertson JS, Excler JL, Condit RC, Fast PE, Gurwith M, Pavlakis G, Monath TP, Smith J, Wood D, Smith ER, Chen RT, Kochhar S; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kim D, et al. Vaccine. 2020 Jul 22;38(34):5556-5561. doi: 10.1016/j.vaccine.2020.06.017. Epub 2020 Jun 19. Vaccine. 2020. PMID: 32571717 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
Volkmann A, Williamson AL, Weidenthaler H, Meyer TPH, Robertson JS, Excler JL, Condit RC, Evans E, Smith ER, Kim D, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. Volkmann A, et al. Vaccine. 2021 May 21;39(22):3067-3080. doi: 10.1016/j.vaccine.2020.08.050. Epub 2020 Oct 17. Vaccine. 2021. PMID: 33077299 Free PMC article. Review.
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Electronic address: [email protected]. Kochhar S, et al. Vaccine. 2020 Sep 3;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747214 Free PMC article.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, Heijnen E, Condit R, Shukarev G, Heerwegh D, van Heesbeen R, Schuitemaker H, Douoguih M, Evans E, Smith ER, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Custers J, et al. Vaccine. 2021 May 21;39(22):3081-3101. doi: 10.1016/j.vaccine.2020.09.018. Epub 2020 Oct 3. Vaccine. 2021. PMID: 33676782 Free PMC article. Review.
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Vaccine. 2015. PMID: 25446819 Free PMC article. Review.
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.
Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Condit RC, et al. Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Vaccine. 2016. PMID: 27346303 Free PMC article. Review.
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11. Vaccine X. 2019. PMID: 31384731 Free PMC article.
Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.
Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Kochhar S, et al. Vaccine. 2019 Sep 10;37(38):5796-5802. doi: 10.1016/j.vaccine.2018.08.085. Epub 2018 Nov 26. Vaccine. 2019. PMID: 30497831 Free PMC article.